www.hepatology-druginteractions.org			UNIVERSITY OF LIVERPOOL
		Interaction Report	
Report ID: Date Produced:	03 May 2025		
Hepatology Treatment		Co-medications	
Bulevirtide		Darunavir/cobicistat	

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown. Please note that some co-medications with a green classification may require dose adjustment due to hepatic impairment.

For full details of all interactions, see www.hepatology-druginteractions.org .

Description of the interactions

Drugs that should not be coadministered (RED)

Bulevirtide + Darunavir/cobicistat

Bulevirtide is catabolized by peptidases and elimination occurs through binding to NTCP. Coadministration with NTCP inhibitors (e.g. ritonavir) is not recommended as it can alter bulevirtide elimination. This recommendation applies also to cobicistat as an inhibitory effect on NTCP cannot be excluded.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

The specific plant provided for information only, it is not intended to replace a possibility of an autoconcertain plant plant